Compare TRIB & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | NXL |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | 7 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 8.3M |
| IPO Year | 1996 | N/A |
| Metric | TRIB | NXL |
|---|---|---|
| Price | $0.77 | $0.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 152.0K | ★ 211.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.51 | $38.28 |
| Revenue Next Year | $13.14 | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.37 |
| 52 Week High | $3.44 | $2.57 |
| Indicator | TRIB | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 38.72 |
| Support Level | $0.65 | $0.42 |
| Resistance Level | $0.79 | $0.62 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 84.28 | 9.31 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.